Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 22;7(6):903–910. doi: 10.1002/acn3.51041

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Survival rates after the onset of the disease in FTLD patients according to sNfL levels and C9orf72 genetic status. (A) Graph showing that the group with higher sNfL levels had a lower survival rate than those with low or moderate sNfL levels. The groups were formulated by dividing the whole FTLD cohort into three equally sized (n = 26) groups according to their sNfL levels (low < 26.1 pg/mL, moderate 26.1–44.4 pg/mL, and high> 44.4 pg/mL). Differences in survival among groups were statistically significant (P < 0.001) (B) Graph showing survival rates of the C9orf72 repeat expansion carriers (n = 26) and non‐carriers (n = 52). The difference in survival rate showed a trend of shorter survival of C9orf72 carriers compared to non‐carriers; however, the difference was not statistically significant (P = 0.080).